spacer
home > ebr > winter 2003 > is resistance futile?
PUBLICATIONS
European Biopharmaceutical Review

Is Resistance Futile?

Resistance is futile, or so the battle cry of the new enemy of humans in Star Trek goes. However resistance is hardly futile in the case of the retrovirus HIV. To date, HIV has infected 42 million people worldwide. In 2002 there were five million new infections and three million people died as a result of HIV infection or its end result - acquired immune deficiency syndrome (AIDS). The latest figures suggest that one person worldwide is infected with HIV every 60 seconds and 70 per cent of the burden of the world's HIV epidemic is carried by sub-Saharan Africa.

Since HIV-1 was isolated in 1984 and the cause of AIDS discovered, the innovation in drug development has been unrelenting. HIV infects and destroys human CD4 receptor positive cells in human hosts. This destruction leads to a loss of the cellular immune response and thus a switch of the immune system from a TH1 response to a TH2 one. The destruction of CD4+ cells is caused by the assembly of new HIV virus particles and their final budding out of the infected cell.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr DC Herath, Senior Medical Advisor in HIV at Roche UK

Dr DC Herath completed his Medical Degree at St Mary's Hospital Medical School, London. During that time, Dr Herath also completed a BSc in Haematology, conducting a study into thrombophilic disorders in recurrent miscarriage women. Having graduated, he spent several years as SHO in the major specialities (Renal, Neurology, Cardiology, Gastroenterology, Respiratory and ID/HIV) all at St Mary's, and then worked as SpR in HIV at St Mary's before moving to Roche as Clinical Science Specialist on the TORO 2 study in February 2002. In June of this year, Dr Herath undertook the post of Senior Medical Advisor in HIV for the Roche UK affiliate, overseeing the whole HIV portfolio from a medical viewpoint. He is still a practising physician in HIV, with a patient list of 80 at St Mary's Hospital in London.

spacer
Dr DC Herath
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm’s CSO and University of Reading Professor co-author new book on dermal formulation development

MedPharm’s Chief Scientific Officer and Co-Founder, Professor Marc Brown and University of Reading’s Professor Adrian Williams have co-authored the new book: ‘The Art and Science of Dermal Formulation Development”. It is the latest addition to ‘Drugs and the Pharmaceutical Sciences’, a series of textbooks and monographs published by CRC Press.
More info >>

White Papers

Technology Solutions - Driving efficiencies, quality and operational excellence

Worldwide Clinical Trials Ltd

Clinical trials involve the entry, analysis and reporting of millions of pieces of data; year-on-year, the amount of data required to manage efficacy and safety increases exponentially. Recently, solutions available to support this activity have grown in numbers and complexity. The rise of Tablets and Smart Phones combined with the growth of Cloud or SAS solutions has resulted in the technology landscape required to support complex, global studies becoming more confusing.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement